Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China
- 31 July 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Hepatology International
- Vol. 1 (3), 365-372
- https://doi.org/10.1007/s12072-007-9009-2
Abstract
Chronic hepatitis B has a high prevalence (>8%) in China. We compared the safety and efficacy of entecavir with that of lamivudine for the treatment of patients with chronic hepatitis B in China.Keywords
This publication has 16 references indexed in Scilit:
- Chronic hepatitis BHepatology, 2007
- A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An UpdateClinical Gastroenterology and Hepatology, 2006
- Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 updateLiver International, 2005
- Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver DiseaseThe New England Journal of Medicine, 2004
- Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis BClinical Infectious Diseases, 2003
- Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis BThe New England Journal of Medicine, 2003
- Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis BThe New England Journal of Medicine, 2003
- Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infectionGastroenterology, 2002
- Long‐Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis InfectionThe Journal of Infectious Diseases, 2001
- Hepatitis B Virus InfectionThe New England Journal of Medicine, 1997